Stability of polymeric cationic niosomes and their plasmid DNA-based complexes as gene delivery carriers

Drug Deliv. 2023 Dec;30(1):2219420. doi: 10.1080/10717544.2023.2219420.

Abstract

This study aims to explore the stability of lipo-polymeric niosomes/niosome-based pCMS-EGFP complexes under different storage temperatures (25 °C, 4 °C, and -20 °C). To date, the question of nucleic acid-complex stability is one of the most vital issues in gene delivery applications. The need for stable vaccines during the COVID-19 pandemic has merely highlighted it. In the case of niosomes as gene carriers, the scientific literature still lacks comprehensive stability studies. In this study, the physicochemical features of niosomes/nioplexes in terms of size, surface charge, and polydispersity index (PDI), along with transfection efficiency, and cytotoxicity in NT2 cells were evaluated for 8 weeks. Compared to day 0, the physicochemical features of the niosomes stored at 25 °C and -20 °C changed dramatically in terms of size, zeta potential, and PDI, while remaining in reasonable values when stored at 4 °C. However, niosomes and nioplexes stored at 4 °C and -20 °C showed nearly stable transfection efficiency values, yet an obvious decrease at 25 °C. This article provides a proof of concept into the stability of polymeric cationic niosomes and their nioplexes as promising gene delivery vehicles. Moreover, it highlights the practical possibility of storing nioplexes at 4 °C for up to 2 months, as an alternative to niosomes, for gene delivery purposes.

Keywords: Stability; cationic niosome; gene delivery; nioplexes; non-viral vectors.

MeSH terms

  • COVID-19*
  • DNA
  • Humans
  • Liposomes* / chemistry
  • Pandemics
  • Plasmids
  • Polymers

Substances

  • Liposomes
  • DNA
  • Polymers

Grants and funding

This work was supported by the Basque Country Government (Department of Education, University and Research, Consolidated Groups IT907-16). Additional funding was provided by the CIBER of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), an initiative of the Carlos III Health Institute (ISCIII).